ZLAB Zai Lab Limited

34.04
-0.08  -0%
Previous Close 34.12
Open 34.23
Price To Book 7.92
Market Cap 2,293,462,394
Shares 67,375,511
Volume 94,501
Short Ratio
Av. Daily Volume 185,660
Stock charts supplied by TradingView

NewsSee all news

  1. Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

    SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Dr. Samantha Du,

  2. Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

    The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published in The New England Journal of Medicine, demonstrates that niraparib treatment

  3. Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019

    -- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT-- SHANGHAI, China and SAN FRANCISCO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB), a China and

  4. Zai Lab Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 3, 2019 / Zai Lab Ltd. (NASDAQ:ZLAB) will be discussing their earnings results in their 2019 First Half Earnings to be held on September 3, 2019 at 8:30 AM Eastern Time.To listen to

  5. Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients

    Study demonstrated comparable profile to non-Chinese patientsClinical study published in The Oncologist SHANGHAI, China, and SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a China and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 dosing initiated - noted June 29. 2018.
ZL-2306 (niraparib)
First-line maintenance therapy for platinum-responsive ovarian cancer
China NDA filing announced December 12, 2018.
ZL-2306 (niraparib)
Recurrent platinum-sensitive ovarian cancer
Phase 3 data met PFS primary endpoint - August 13, 2019. Presentation at ESMO 2019 noted median PFS of 6.3 months. ORR endpoint not met.
Ripretinib DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 3 futility analysis due 1H 2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 3 data released July 15, 2019 met primary endpoint. Presentation at ESMO 2019 noted PFS, HR 0.62.
Niraparib - PRIMA
First-line ovarian cancer
Second interim overall survival analysis and BLA filing due 4Q 2019.
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 2 data due 4Q 2019.
Omadacycline
Urinary tract infections
Phase 3 top-line data due 2H 2020.
ETX2514SUL
Acinetobacter baumannii infections
Phase 2 data due 4Q 2019.
Omadacycline
Complicated urinary tract infections (cUTI) / acute pyelonephritis

Latest News

  1. Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

    SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Dr. Samantha Du,

  2. Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

    The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published in The New England Journal of Medicine, demonstrates that niraparib treatment

  3. Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019

    -- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT-- SHANGHAI, China and SAN FRANCISCO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB), a China and

  4. Zai Lab Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 3, 2019 / Zai Lab Ltd. (NASDAQ:ZLAB) will be discussing their earnings results in their 2019 First Half Earnings to be held on September 3, 2019 at 8:30 AM Eastern Time.To listen to

  5. Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients

    Study demonstrated comparable profile to non-Chinese patientsClinical study published in The Oncologist SHANGHAI, China, and SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a China and

  6. Zai Lab Announces Upcoming Presentations at September Conferences

    SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB), a China and US-based innovative commercial-stage biopharmaceutical company, today